Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients

Chiara Pavanello, Andrea Baragetti, Adriana Branchi, Liliana Grigore, Samuela Castelnuovo, Eleonora Giorgio, Alberico L. Catapano, L. Calabresi, Monica Gomaraschi

Research output: Contribution to journalArticle

Abstract

Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis of lipids. Since there are no indications about the effect of different lipid-lowering agents on LAL activity, aim of the study was to address the relationship between LAL activity and the type of lipid-lowering therapy in a cohort of dyslipidemic patients. LAL activity was measured on dried blood spot from 120 patients with hypercholesterolemia or mixed dyslipidemia and was negatively correlated to LDL-cholesterol levels. Among enrolled patients, ninety-one were taking one or more lipid-lowering drugs, as statins, fibrates, ezetimibe and omega-3 polyunsaturated fatty acids. When patients were stratified according to the type of lipid-lowering treatment, i.e. untreated, taking statins or taking fibrates, LAL activity was significantly higher in those with fibrates, even after adjustment for sex, age, BMI, lipid parameters, liver function, metabolic syndrome, diabetes and statin use. In a subset of patients tested after 3 months of treatment with micronized fenofibrate, LAL activity raised by 21%; the increase was negatively correlated with baseline LAL activity. Thus, the use of fibrates is independently associated with higher LAL activity in dyslipidemic patients, suggesting that the positive effects of PPAR-α activation on cellular and systemic lipid homeostasis can also include an improved LAL activity.

Original languageEnglish
Article number104362
JournalPharmacological Research
Volume147
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Sterol Esterase
Fibric Acids
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Cholesterol Esters
Nonesterified Fatty Acids
Cytosol
Triglycerides
Homeostasis
Cholesterol
Fenofibrate
Peroxisome Proliferator-Activated Receptors
Omega-3 Fatty Acids
Dyslipidemias
Lysosomes
Hypercholesterolemia
Unsaturated Fatty Acids
LDL Cholesterol
Hydrolysis

Keywords

  • Dyslipidemia
  • Fibrates
  • Lysosomal acid lipase
  • Statins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. / Pavanello, Chiara; Baragetti, Andrea; Branchi, Adriana; Grigore, Liliana; Castelnuovo, Samuela; Giorgio, Eleonora; Catapano, Alberico L.; Calabresi, L.; Gomaraschi, Monica.

In: Pharmacological Research, Vol. 147, 104362, 01.09.2019.

Research output: Contribution to journalArticle

Pavanello, Chiara ; Baragetti, Andrea ; Branchi, Adriana ; Grigore, Liliana ; Castelnuovo, Samuela ; Giorgio, Eleonora ; Catapano, Alberico L. ; Calabresi, L. ; Gomaraschi, Monica. / Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. In: Pharmacological Research. 2019 ; Vol. 147.
@article{7c20ec40d0e34c7bbec6b2d0e7568327,
title = "Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients",
abstract = "Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis of lipids. Since there are no indications about the effect of different lipid-lowering agents on LAL activity, aim of the study was to address the relationship between LAL activity and the type of lipid-lowering therapy in a cohort of dyslipidemic patients. LAL activity was measured on dried blood spot from 120 patients with hypercholesterolemia or mixed dyslipidemia and was negatively correlated to LDL-cholesterol levels. Among enrolled patients, ninety-one were taking one or more lipid-lowering drugs, as statins, fibrates, ezetimibe and omega-3 polyunsaturated fatty acids. When patients were stratified according to the type of lipid-lowering treatment, i.e. untreated, taking statins or taking fibrates, LAL activity was significantly higher in those with fibrates, even after adjustment for sex, age, BMI, lipid parameters, liver function, metabolic syndrome, diabetes and statin use. In a subset of patients tested after 3 months of treatment with micronized fenofibrate, LAL activity raised by 21{\%}; the increase was negatively correlated with baseline LAL activity. Thus, the use of fibrates is independently associated with higher LAL activity in dyslipidemic patients, suggesting that the positive effects of PPAR-α activation on cellular and systemic lipid homeostasis can also include an improved LAL activity.",
keywords = "Dyslipidemia, Fibrates, Lysosomal acid lipase, Statins",
author = "Chiara Pavanello and Andrea Baragetti and Adriana Branchi and Liliana Grigore and Samuela Castelnuovo and Eleonora Giorgio and Catapano, {Alberico L.} and L. Calabresi and Monica Gomaraschi",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.phrs.2019.104362",
language = "English",
volume = "147",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients

AU - Pavanello, Chiara

AU - Baragetti, Andrea

AU - Branchi, Adriana

AU - Grigore, Liliana

AU - Castelnuovo, Samuela

AU - Giorgio, Eleonora

AU - Catapano, Alberico L.

AU - Calabresi, L.

AU - Gomaraschi, Monica

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis of lipids. Since there are no indications about the effect of different lipid-lowering agents on LAL activity, aim of the study was to address the relationship between LAL activity and the type of lipid-lowering therapy in a cohort of dyslipidemic patients. LAL activity was measured on dried blood spot from 120 patients with hypercholesterolemia or mixed dyslipidemia and was negatively correlated to LDL-cholesterol levels. Among enrolled patients, ninety-one were taking one or more lipid-lowering drugs, as statins, fibrates, ezetimibe and omega-3 polyunsaturated fatty acids. When patients were stratified according to the type of lipid-lowering treatment, i.e. untreated, taking statins or taking fibrates, LAL activity was significantly higher in those with fibrates, even after adjustment for sex, age, BMI, lipid parameters, liver function, metabolic syndrome, diabetes and statin use. In a subset of patients tested after 3 months of treatment with micronized fenofibrate, LAL activity raised by 21%; the increase was negatively correlated with baseline LAL activity. Thus, the use of fibrates is independently associated with higher LAL activity in dyslipidemic patients, suggesting that the positive effects of PPAR-α activation on cellular and systemic lipid homeostasis can also include an improved LAL activity.

AB - Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis of lipids. Since there are no indications about the effect of different lipid-lowering agents on LAL activity, aim of the study was to address the relationship between LAL activity and the type of lipid-lowering therapy in a cohort of dyslipidemic patients. LAL activity was measured on dried blood spot from 120 patients with hypercholesterolemia or mixed dyslipidemia and was negatively correlated to LDL-cholesterol levels. Among enrolled patients, ninety-one were taking one or more lipid-lowering drugs, as statins, fibrates, ezetimibe and omega-3 polyunsaturated fatty acids. When patients were stratified according to the type of lipid-lowering treatment, i.e. untreated, taking statins or taking fibrates, LAL activity was significantly higher in those with fibrates, even after adjustment for sex, age, BMI, lipid parameters, liver function, metabolic syndrome, diabetes and statin use. In a subset of patients tested after 3 months of treatment with micronized fenofibrate, LAL activity raised by 21%; the increase was negatively correlated with baseline LAL activity. Thus, the use of fibrates is independently associated with higher LAL activity in dyslipidemic patients, suggesting that the positive effects of PPAR-α activation on cellular and systemic lipid homeostasis can also include an improved LAL activity.

KW - Dyslipidemia

KW - Fibrates

KW - Lysosomal acid lipase

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85069833802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069833802&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2019.104362

DO - 10.1016/j.phrs.2019.104362

M3 - Article

AN - SCOPUS:85069833802

VL - 147

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

M1 - 104362

ER -